Salazar, N PCarlos, C CBustos, D GQuiambao, B PSaniel, M CSantos, M N2009-05-272009-05-271991-09-01Salazar NP, Carlos CC, Bustos DG, Quiambao BP, Saniel MC, Santos MN. Halofantrine in the treatment of acute uncomplicated falciparum malaria in the Philippines. The Southeast Asian Journal of Tropical Medicine and Public Health. 1991 Sep; 22(3): 386-92http://imsear.searo.who.int/handle/123456789/33484The Southeast Asian Journal of Tropical Medicine and Public Health.In an open clinical trial, thirty patients 14 to 44 years old and with acute uncomplicated falciparum malaria were given halofantrine hydrochloride 500 mg (2 tablets) 6-hourly for 3 doses, a total dose of 1500 mg. All 30 patients were cured, with a mean asexual parasite clearance time of 47.6 hours and mean fever clearance time of 36.6 hours. Post-dosing side-effects occurred in 6 patients consisting of mild to moderate headache, dizziness and abdominal muscle spasm. Drug-induced hemolysis did not occur in two G6PD deficient patients. Twenty-three out of 28 isolates tested (82%) were resistant to amodiaquine, 3 (11%) were resistant to the sulfadoxine-pyrimethamine combination, and all were sensitive to chloroquine, quinine and mefloquine by in vitro microtests. The study confirms the efficacy of halofantrine hydrochloride as a blood schizonticide in falciparum malaria.engAcute DiseaseAdministration, OralAdolescentAdultBlood Cell CountBlood Chemical AnalysisDrug ResistanceHematocritHemoglobins --analysisHumansMalaria, Falciparum --bloodParasite Egg CountPhenanthrenes --administration & dosageClinical Trial